l General Information |
Product Name | Lenvatinib mesylate |
General description | Lenvatinib mesylate is a synthetic, orally available inhibitor of VEGFR2 tyrosine kinase with potential antineoplastic activity. |
Synonym | E7080; Lenvatinib mesilate |
Purity | ≥98%(HPLC) | CAS Number | 857890-39-2 |
Formula | C22H23ClN4O7S | Molecular Weight | 522.957 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | White or Off-white solid |
l Biological Information |
Biochem/Physiol Actions | Lenvatinib Mesylate is a synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic activity. E7080 blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis. |
l Packaging & Storage |
Packaging | 25mg; 250mg |
Storage temp. | 0-5℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
